Elsevier

Fertility and Sterility

Volume 63, Issue 6, June 1995, Pages 1326-1328
Fertility and Sterility

Communications-in-brief
Recombinant human follicle-stimulating hormone* and human chorionic gonadotropin for induction of spermatogenesis in a hypogonadotropic male

https://doi.org/10.1016/S0015-0282(16)57619-5Get rights and content
Under an Elsevier user license
open archive

Objective

To determine the efficacy of recombinant FSH administration to induce spermatogenesis.

Design

Case report, clinical study.

Setting

Tertiary center for reproductive medicine of the university.

Patient

A 44-year-old hypogonadal man with postpubertal pituitary insufficiency due to surgical removal of a prolactinoma.

Interventions

Recombinant FSH (150 IU three times weekly) was administered together with hCG (1,500 IU twice weekly). Control examinations were performed every 6 weeks, including hormone determinations, safety parameters, testicular volume measurements, and semen analysis.

Main Outcome Measure

Semen parameters.

Results

After 18 weeks of treatment, first sperm were seen in the ejaculate and reached normal sperm concentrations after 24 weeks of treatment. Serum hormone levels were in the normal range and testicular volume increased. No adverse side effects were observed.

Conclusions

Recombinant human FSH in combination with hCG can be used successfully for stimulation of testicular function in gonadotropin-deficient men.

Key Words

Recombinant human FSH
male hypogonadotropic hypogonadism
spermatogenesis
gonadotropin therapy

Cited by (0)

*

Study medication was supplied by Organon International, Oss, The Netherlands.

Supported by the Deutsche Forschungsgemeinschaft, Bonn, Germany (Ni 130/11).

Reprint requests: Eberhard Nieschlag, Dr. med., Institute of Reproductive Medicine, Steinfurter Straße 107, D-48149 Münster, Germany (FAX: 49–251–836093).